

**Project ECHO for Interstitial Lung Disease**

Wednesday, February 4, 2026, 7am-8am ET

Medical Director	Robert Hallowell, MD
Principal Investigator	Aliaa Barakat, PhD
Didactic Speaker	Grace Peloquin, MD
Discussion Facilitator	Fiona Gibbons, MD
Target Audience	The series is designed for pulmonologists, radiologists and other health providers who care for people with ILD.

**In accordance with HIPAA:** All PHI will be de-identified during the session.

Time	Didactic Presentation / Case Discussion	Presenter / Facilitator
7:00am-7:05am	Announcements and Introductions	Aliaa Barakat, PhD Robert Hallowell, MD
7:05am-7:25am	Didactic: Lung Cancer in Patients with ILD — Diagnostic and Management Considerations	Grace Peloquin, MD
7:25am-8:00am	Case Presentation and Discussion	Fiona Gibbons, MD
8am	Closing Remarks	Robert Hallowell, MD

**Didactic Learning Objectives:**

1. Understand the magnitude of lung cancer risk in patients with ILD.
2. Recognize diagnostic challenges including difficulty identifying cancerous lesions on imaging (parenchymal masking) and risk of tissue sampling.
3. Evaluate the risk-benefit ratio of each treatment approach (surgical resection, radiotherapy, systemic therapy, immunotherapy). Recognizing acute exacerbation of ILD is most feared complication across all treatment modalities.
4. Understand prognostic implications, including that median overall survival for ILD-lung cancer patients is significantly worse than lung cancer alone, though better than no treatment, emphasizing need for early detection and individualized treatment strategies.

ECHO case discussions are intended solely for educational purposes and are not meant to serve as a consultation or as a mechanism for providing formal recommendations on treatment and other management decisions, which remain the sole responsibility of the treating provider.

**Chobanian & Avedisian School of Medicine**

Barry M. Manuel Center for Continuing Education



In support of improving patient care, this activity has been planned and implemented by the ILD Collaborative and Boston University Chobanian & Avedisian School of Medicine. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**American Board of Pathology Maintenance of Certification (MOC) Part 2 Credit**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 22.0 MOC points in the American Board of Pathology's (ABPath) Maintenance of Certification (MOC) program. Credit type: Lifelong Learning (CME).

*By participating and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABIM and ABPath.*

**Physician Accreditation**

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurse Accreditation**

Nursing Contact Hours: 1.0, all of which is eligible for pharmacology credit.

This activity is supported by the ILD Collaborative and by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.

## Disclosure Policy

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

None of the following planners / presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Aliaa Barakat, PhD, Katharine Black, MD, Fiona Gibbons, MD, and Grace Peloquin, MD.

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

Name	Disclosure of Relevant Financial Relationship
Leo Ginns, MD	Dr. Ginns is a clinical trial site principal investigator for United Therapeutics.
Robert Hallowell, MD	Dr. Hallowell has served on advisory boards and as an investigator for Boehringer Ingelheim. He has served as a consultant and an investigator for Vicore. He has also been a consultant for Merck and receives authorship fees from Up-to-Date and Dynamed. He is also on the advisory boards for Arcellx and Puretech.
Sydney Montesi, MD	Dr. Montesi is a consultant and on the clinical adjudication committee for AbbVie. She is also a consultant for Amgen, Accendatech, and Mediar Therapeutics. She receives research funding from Boehringer Ingelheim, and Pliant Therapeutics via her institution. She also receives authorship fees from Wolters Kluwer.
Barry Shea, MD	Dr. Shea is a clinical trial site principal investigator for Boehringer Ingelheim, Bristol Myers Squibb, and Mediar Therapeutics. He has served as a consultant for Continuum Therapeutics, Radius Health, and United Therapeutics.

All of the relevant financial relationships listed for these individuals have been mitigated.

### Accreditor Disclosure:

Michael Burk, Senior Operations Manager for Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education, has no relevant financial relationships to disclose.

### Accreditor Disclosure:

The faculty does plan on discussing unlabeled/investigational uses of a commercial product.

This session will be audio and video recorded.  
Your participation confirms your consent to this recording.

---

## Credit Claiming Instructions

### CME and CNE

1. To claim your credit for this ECHO Session, please go to this link:

[Lung Cancer in Patients with ILD: Diagnostic and Management Considerations | Chobanian & Avedisian School of Medicine/CCE](#)

- a) Click on "Take Course" on the right-hand side.
  - b) Click on "Take-Course" in the Course Progress bar on the left to begin the evaluation survey and complete the credit claiming process.
  - c) A certificate will be available to download or stored in your account under "My Activities".
2. If you do not have an account, you will be prompted to create one. Once you do, the site will bring you directly back to the session to claim credit.

### MOC II Credit

1. Update your profile within BU's credit claiming system (<https://cme.bu.edu>) to ensure it includes:
  - a) Your ABIM Board ID number.
  - b) Your date of birth (MM/DD).
2. The evaluation survey must be completed by Wednesday, 2/11/2026.
3. Credit will be posted within 24-48 hours with the ABIM.

## DISCLAIMER

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

---